{"id":"placebo-10-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nocebo effects (adverse events attributed to placebo expectation)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo is an inert substance that lacks direct pharmacological activity. Its therapeutic effects arise from the patient's expectation of benefit, conditioning, and activation of endogenous healing mechanisms including neurobiological pathways. Placebo responses are well-documented across multiple therapeutic areas and serve as the control comparator in randomized clinical trials.","oneSentence":"Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, rather than through a pharmacologically active ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:26.758Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control comparator (non-therapeutic use)"}]},"trialDetails":[{"nctId":"NCT06097663","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-15","conditions":"Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)","enrollment":31},{"nctId":"NCT07433556","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2026-03-23","conditions":"Healhty","enrollment":86},{"nctId":"NCT05377424","phase":"PHASE1, PHASE2","title":"Adenosine 2A Receptor Antagonism and AIH in ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-06-21","conditions":"ALS","enrollment":40},{"nctId":"NCT05855824","phase":"NA","title":"Toddler Biomarker of Nutrition Study","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06-01","conditions":"Pediatric Nutrition, Nutrition, Healthy","enrollment":150},{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT07498712","phase":"NA","title":"Effect of L. Reuteri LM1063 on Sleep Health Improvement","status":"RECRUITING","sponsor":"Lactomason Co., Ltd.","startDate":"2025-07-14","conditions":"Sleep Quality, Sleep Wake Disorders","enrollment":80},{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT05630781","phase":"NA","title":"Orexin s Role in the Neurobiology of Substance Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-02-15","conditions":"Nicotine Dependence","enrollment":140},{"nctId":"NCT07497685","phase":"NA","title":"Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-10-10","conditions":"Exercise Performance, Physical Performance","enrollment":14},{"nctId":"NCT07210515","phase":"PHASE3","title":"Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)","status":"RECRUITING","sponsor":"Ambros Therapeutics, Inc.","startDate":"2026-03","conditions":"Complex Regional Pain Syndrome Type I","enrollment":270},{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT07497776","phase":"PHASE4","title":"Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome","status":"COMPLETED","sponsor":"National Institute of Kidney Disease and Urology (NIKDU)","startDate":"2024-01-27","conditions":"Dyslipidaemia","enrollment":100},{"nctId":"NCT06280235","phase":"PHASE2","title":"A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-27","conditions":"Depressive Disorder, Major","enrollment":243},{"nctId":"NCT06031844","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-16","conditions":"Coronary Heart Disease","enrollment":24},{"nctId":"NCT06778122","phase":"NA","title":"In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors","status":"RECRUITING","sponsor":"University College, London","startDate":"2026-01-23","conditions":"Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs","enrollment":10},{"nctId":"NCT07488689","phase":"PHASE3","title":"Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-07","conditions":"Septic Shock","enrollment":568},{"nctId":"NCT02548559","phase":"PHASE2","title":"Sublingual Cannabidiol for Anxiety","status":"COMPLETED","sponsor":"Staci Gruber, Ph.D.","startDate":"2018-08-14","conditions":"Anxiety","enrollment":46},{"nctId":"NCT05540574","phase":"PHASE2","title":"Trial of Zolpidem for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT06732245","phase":"PHASE2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-08-15","conditions":"Obesity and Overweight","enrollment":224},{"nctId":"NCT05143177","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)","status":"SUSPENDED","sponsor":"REDNVIA Co., Ltd.","startDate":"2022-06-27","conditions":"Calcific Aortic Valve Disease","enrollment":580},{"nctId":"NCT05072314","phase":"PHASE3","title":"Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial","status":"RECRUITING","sponsor":"Monash University","startDate":"2022-07-27","conditions":"Breast Cancer, Breast Cancer Female, Breast Conserving Surgery","enrollment":4300},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":"Acute Uncomplicated Diverticulitis","enrollment":100},{"nctId":"NCT07264192","phase":"PHASE1","title":"A Study of HS-10518 in Healthy Adult Premenopausal Females in China","status":"COMPLETED","sponsor":"West China Second University Hospital","startDate":"2025-03-11","conditions":"Infertility, Female","enrollment":60},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT06337838","phase":"PHASE3","title":"Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-06-09","conditions":"Chronic Kidney Diseases, Acute Kidney Injury, Bleeding","enrollment":100},{"nctId":"NCT05458609","phase":"PHASE3","title":"Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2023-02-09","conditions":"Alcohol Use Disorder","enrollment":8},{"nctId":"NCT05291091","phase":"PHASE2","title":"Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edgewise Therapeutics, Inc.","startDate":"2022-11-10","conditions":"Becker Muscular Dystrophy","enrollment":244},{"nctId":"NCT06269393","phase":"PHASE3","title":"A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Thyroid Associated Ophthalmopathy","enrollment":53},{"nctId":"NCT04720534","phase":"PHASE2","title":"Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2021-05-31","conditions":"Severe Hypertriglyceridemia","enrollment":229},{"nctId":"NCT05677763","phase":"PHASE4","title":"OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness","status":"ACTIVE_NOT_RECRUITING","sponsor":"OM Pharma SA","startDate":"2022-12-12","conditions":"Respiratory Tract Infections, Wheezing Lower Respiratory Illness","enrollment":525},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT06655883","phase":"PHASE3","title":"A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-09","conditions":"Insomnia","enrollment":300},{"nctId":"NCT04472598","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-29","conditions":"Myelofibrosis (MF)","enrollment":252},{"nctId":"NCT06934915","phase":"EARLY_PHASE1","title":"Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Christopher John McDougle, M.D.","startDate":"2026-11","conditions":"Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder","enrollment":32},{"nctId":"NCT04924608","phase":"PHASE3","title":"Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-11-19","conditions":"Neurofibromatosis 1, Plexiform Neurofibroma (PN)","enrollment":145},{"nctId":"NCT07487545","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2026-03-31","conditions":"Healthy","enrollment":52},{"nctId":"NCT05452564","phase":"PHASE2","title":"Baricitinib for Reduction of HIV - CNS","status":"RECRUITING","sponsor":"William Tyor","startDate":"2023-05-18","conditions":"Human Immunodeficiency Virus","enrollment":95},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT06547489","phase":"PHASE2","title":"Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","sponsor":"Syndeio Biosciences, Inc","startDate":"2025-02-03","conditions":"Major Depressive Disorder","enrollment":164},{"nctId":"NCT06667700","phase":"PHASE3","title":"A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-02","conditions":"Coronavirus Disease (COVID-19)","enrollment":3082},{"nctId":"NCT04597372","phase":"PHASE2","title":"Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery","status":"RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2021-11-03","conditions":"Urinary Retention Postoperative","enrollment":154},{"nctId":"NCT03970720","phase":"PHASE2","title":"Restoration of Hypoglycemia Awareness With Metoclopramide","status":"RECRUITING","sponsor":"Simon Fisher","startDate":"2019-05-28","conditions":"Hypoglycemia Unawareness","enrollment":36},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT06512389","phase":"PHASE2","title":"Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-08-16","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT05714085","phase":"PHASE2, PHASE3","title":"Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-31","conditions":"Heart Failure, Left Ventricular Systolic Dysfunction","enrollment":342},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT06229483","phase":"PHASE3","title":"The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies","status":"RECRUITING","sponsor":"Stephen Lownie","startDate":"2024-04-03","conditions":"Brain Tumor, Bleeding","enrollment":102},{"nctId":"NCT06828861","phase":"PHASE3","title":"ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial","status":"SUSPENDED","sponsor":"Aardvark Therapeutics, Inc.","startDate":"2024-12-20","conditions":"Hyperphagia, Prader-Willi Syndrome","enrollment":90},{"nctId":"NCT07481747","phase":"PHASE3","title":"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","enrollment":2539},{"nctId":"NCT06554301","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-10-20","conditions":"Pulmonary Arterial Hypertension","enrollment":72},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":"Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity","enrollment":300},{"nctId":"NCT07483346","phase":"PHASE1","title":"IASO-782 in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Shanghai IASO Biotechnology Co., Ltd","startDate":"2026-04-30","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT07093463","phase":"NA","title":"Colon-delivered Riboflavin and Gut Microbiota Composition","status":"RECRUITING","sponsor":"dsm-firmenich Switzerland AG","startDate":"2025-07-18","conditions":"Microbiome Dysbiosis, Gut Health","enrollment":90},{"nctId":"NCT07480096","phase":"PHASE2","title":"Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2024-10-01","conditions":"Cirrhosis, Liver Cirrhosis, Sleep Quality","enrollment":82},{"nctId":"NCT07475208","phase":"NA","title":"NR and Exercise for Blood Pressure","status":"NOT_YET_RECRUITING","sponsor":"ZHANG Jiaqi","startDate":"2026-04","conditions":"Hypertension (HTN)","enrollment":112},{"nctId":"NCT01233297","phase":"PHASE2","title":"Antibiotic Treatment of Recurrent Episodes of Asthma in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Studies on Asthma in Childhood","startDate":"2010-11","conditions":"Childhood Asthma With Acute Exacerbation","enrollment":70},{"nctId":"NCT07184801","phase":"PHASE3","title":"Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-10-01","conditions":"Medical Thoracoscopy","enrollment":56},{"nctId":"NCT05653258","phase":"PHASE2, PHASE3","title":"Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2023-10-17","conditions":"Obesity, Healthy Lifestyle","enrollment":160},{"nctId":"NCT07479550","phase":"PHASE2","title":"Anesthesia-Masked Psilocybin Therapy for Major Depression","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-07","conditions":"Major Depression","enrollment":10},{"nctId":"NCT07382167","phase":"PHASE3","title":"A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults","status":"RECRUITING","sponsor":"Ardelyx","startDate":"2026-01-13","conditions":"Chronic Idiopathic Constipation (CIC)","enrollment":692},{"nctId":"NCT06164951","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia","status":"COMPLETED","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2023-11-10","conditions":"Achondroplasia","enrollment":114},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT06582888","phase":"EARLY_PHASE1","title":"Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-11-19","conditions":"Nicotine Addiction, Craving","enrollment":200},{"nctId":"NCT07473752","phase":"PHASE1","title":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2023-07-18","conditions":"Phase 1 First-in-human Study Involving Healthy Subjects","enrollment":26},{"nctId":"NCT06966778","phase":"NA","title":"Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Localized Prostate Cancer, Postoperative Urinary Incontinence","enrollment":135},{"nctId":"NCT05612178","phase":"PHASE1","title":"A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-07-26","conditions":"HIV-1","enrollment":105},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT04459117","phase":"PHASE2, PHASE3","title":"Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-10-29","conditions":"Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity","enrollment":804},{"nctId":"NCT06171113","phase":"PHASE1","title":"A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-12-11","conditions":"Malaria, Falciparum","enrollment":156},{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT07471659","phase":"NA","title":"Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels","status":"NOT_YET_RECRUITING","sponsor":"dsm-firmenich Switzerland AG","startDate":"2026-03-01","conditions":"Stress","enrollment":200},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT06708299","phase":"PHASE3","title":"CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)","status":"RECRUITING","sponsor":"Cardiol Therapeutics Inc.","startDate":"2025-04-07","conditions":"Recurrent Pericarditis","enrollment":110},{"nctId":"NCT07273838","phase":"PHASE2","title":"Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-03-05","conditions":"Heart Failure, Acute Kidney Injury","enrollment":130},{"nctId":"NCT06485245","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2025-04-22","conditions":"MASH","enrollment":80},{"nctId":"NCT04666610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-07-29","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":153},{"nctId":"NCT05664477","phase":"PHASE2","title":"PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roberta Brinton","startDate":"2024-01-10","conditions":"Menopause, Cognitive Change, Brain Disorder, Metabolic","enrollment":100},{"nctId":"NCT07471867","phase":"PHASE4","title":"Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-03-17","conditions":"Chronic Coronary Syndrome","enrollment":100},{"nctId":"NCT04468659","phase":"PHASE3","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-07-14","conditions":"Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease","enrollment":1400},{"nctId":"NCT07329088","phase":"NA","title":"Isoleucine Addition Treatment Effects in a Controlled Diet Study","status":"NOT_YET_RECRUITING","sponsor":"Jean L. Fry","startDate":"2026-05-04","conditions":"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight","enrollment":40},{"nctId":"NCT04981561","phase":"PHASE1","title":"Safety and Tolerability of Zelquistinel in Normal Human Volunteers","status":"COMPLETED","sponsor":"Syndeio Biosciences, Inc","startDate":"2016-12-09","conditions":"Major Depressive Disorder","enrollment":68},{"nctId":"NCT04521881","phase":"PHASE3","title":"Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-04-18","conditions":"Traumatic Brain Injury","enrollment":5000},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT05090904","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2021-11-30","conditions":"Cystic Fibrosis","enrollment":29},{"nctId":"NCT05182658","phase":"PHASE3","title":"Empagliflozin in Hypertrophic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-06-01","conditions":"Hypertrophic Cardiomyopathy, Heart Failure","enrollment":250},{"nctId":"NCT07467746","phase":"PHASE2","title":"Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":84},{"nctId":"NCT07466654","phase":"NA","title":"Low-Dose Caffeine and Taurine Effects on Performance","status":"COMPLETED","sponsor":"Ankara University","startDate":"2025-10-15","conditions":"Anaerobic Performance Neuromuscular Performance Cognitive Performance","enrollment":32},{"nctId":"NCT07197944","phase":"PHASE3","title":"Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS","status":"RECRUITING","sponsor":"Zealand Pharma","startDate":"2026-02-11","conditions":"Short Bowel Syndrome","enrollment":90},{"nctId":"NCT04976036","phase":"PHASE2","title":"Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients","status":"RECRUITING","sponsor":"Dr. Romain Lazor","startDate":"2022-05-05","conditions":"Telangiectasia, Hereditary Hemorrhagic","enrollment":48},{"nctId":"NCT07204314","phase":"PHASE3","title":"A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-01","conditions":"Major Depressive Disorder","enrollment":180},{"nctId":"NCT07402369","phase":"PHASE2","title":"Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia","status":"RECRUITING","sponsor":"Shenzhen Kangzhe Biotechnology Co., Ltd.","startDate":"2026-02-19","conditions":"Uterine Fibroids With Menorrhagia","enrollment":120},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT06899815","phase":"PHASE1","title":"Preliminary Human Trials of F230 Tablets","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-05-15","conditions":"Pulmonary Hypertension","enrollment":136},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":102,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (10 mg)","genericName":"Placebo (10 mg)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, rather than through a pharmacologically active ingredient. Used for Clinical trial control comparator (non-therapeutic use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}